A US prosecutor in the case against notorious Turing Pharmaceuticals CEO Martin Shkreli announced on Wednesday that Shkreli had lost $40 million in portfolio value on the account he used to secure his bail. Shrekli’s brokerage account has seen its value drop from $45 million to roughly $5 million since it was frozen as part of the investigation. Most of the equity value was held in KaloBios, a company that he used to run. The company filed for bankruptcy in December.
See the following visualizations which provide a timeline of the Shkreli case, as well as a number of financial figures related to the story.
Martin Shkreli Compensation Over Time
Kalobios Pharmaceuticals Inc. (KBIO) Net Income – Last 5 Quarters
Most Expensive Prescription Drugs
